Drug Search Results
More Filters [+]

SP203

Alternative Names: sp203
Latest Update: 2018-07-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MGLUR Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Institute of Mental Health (NIMH)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SP203

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Schizophrenia|Alzheimer Disease|Parkinson's Disease|Blood Protein Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

07-M-0082

P1

Completed

Schizophrenia|Alzheimer Disease|Parkinson's Disease|Blood Protein Disorders

None

Recent News Events

Date

Type

Title